A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro

Yao Cheng, Lun K. Tsou, Jianfeng Cai, Toshihiro Aya, Ginger E. Dutschman, Elizabeth A. Gullen, Susan P. Grill, Annie Pei Chun Chen, Brett D. Lindenbach, Andrew Hamilton, Yung Chi Cheng

Research output: Contribution to journalArticle

Abstract

Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the search for highly selective protein-binding molecules capable of disrupting the viral life cycle, we have identified a class of anionic tetraphenylporphyrins as potent and specific inhibitors of the HCV replicons. Based on the structure-activity relationship studies reported herein, meso-tetrakis-(3,5- dicarboxy-4,4′-biphenyl) porphyrin was found to be the most potent inhibitor of HCV genotype 1b (Con1) replicon systems but was less effective against the genotype 2a (JFH-1) replicon. This compound induced a reduction of viral RNA and protein levels when acting in the low nanomolar range. Moreover, the compound could suppress replicon rebound in drug-treated cells and exhibited additive to synergistic effects when combined with protease inhibitor BILN 2061 or with IFN-α-2a. Our results demonstrate the potential use of tetracarboxyphenylporphyrins as potent anti-HCV agents.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Replicon
Porphyrins
Hepacivirus
Genotype
Interferons
Viral RNA
Viral Proteins
Structure-Activity Relationship
Protease Inhibitors
Life Cycle Stages
Protein Binding
Antiviral Agents
In Vitro Techniques
Enzymes
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro. / Cheng, Yao; Tsou, Lun K.; Cai, Jianfeng; Aya, Toshihiro; Dutschman, Ginger E.; Gullen, Elizabeth A.; Grill, Susan P.; Chen, Annie Pei Chun; Lindenbach, Brett D.; Hamilton, Andrew; Cheng, Yung Chi.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 1, 01.2010, p. 197-206.

Research output: Contribution to journalArticle

Cheng, Y, Tsou, LK, Cai, J, Aya, T, Dutschman, GE, Gullen, EA, Grill, SP, Chen, APC, Lindenbach, BD, Hamilton, A & Cheng, YC 2010, 'A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro', Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 197-206. https://doi.org/10.1128/AAC.01206-09
Cheng, Yao ; Tsou, Lun K. ; Cai, Jianfeng ; Aya, Toshihiro ; Dutschman, Ginger E. ; Gullen, Elizabeth A. ; Grill, Susan P. ; Chen, Annie Pei Chun ; Lindenbach, Brett D. ; Hamilton, Andrew ; Cheng, Yung Chi. / A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 1. pp. 197-206.
@article{1192c99b70ba486dacfcc7a859f45584,
title = "A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro",
abstract = "Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the search for highly selective protein-binding molecules capable of disrupting the viral life cycle, we have identified a class of anionic tetraphenylporphyrins as potent and specific inhibitors of the HCV replicons. Based on the structure-activity relationship studies reported herein, meso-tetrakis-(3,5- dicarboxy-4,4′-biphenyl) porphyrin was found to be the most potent inhibitor of HCV genotype 1b (Con1) replicon systems but was less effective against the genotype 2a (JFH-1) replicon. This compound induced a reduction of viral RNA and protein levels when acting in the low nanomolar range. Moreover, the compound could suppress replicon rebound in drug-treated cells and exhibited additive to synergistic effects when combined with protease inhibitor BILN 2061 or with IFN-α-2a. Our results demonstrate the potential use of tetracarboxyphenylporphyrins as potent anti-HCV agents.",
author = "Yao Cheng and Tsou, {Lun K.} and Jianfeng Cai and Toshihiro Aya and Dutschman, {Ginger E.} and Gullen, {Elizabeth A.} and Grill, {Susan P.} and Chen, {Annie Pei Chun} and Lindenbach, {Brett D.} and Andrew Hamilton and Cheng, {Yung Chi}",
year = "2010",
month = "1",
doi = "10.1128/AAC.01206-09",
language = "English (US)",
volume = "54",
pages = "197--206",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro

AU - Cheng, Yao

AU - Tsou, Lun K.

AU - Cai, Jianfeng

AU - Aya, Toshihiro

AU - Dutschman, Ginger E.

AU - Gullen, Elizabeth A.

AU - Grill, Susan P.

AU - Chen, Annie Pei Chun

AU - Lindenbach, Brett D.

AU - Hamilton, Andrew

AU - Cheng, Yung Chi

PY - 2010/1

Y1 - 2010/1

N2 - Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the search for highly selective protein-binding molecules capable of disrupting the viral life cycle, we have identified a class of anionic tetraphenylporphyrins as potent and specific inhibitors of the HCV replicons. Based on the structure-activity relationship studies reported herein, meso-tetrakis-(3,5- dicarboxy-4,4′-biphenyl) porphyrin was found to be the most potent inhibitor of HCV genotype 1b (Con1) replicon systems but was less effective against the genotype 2a (JFH-1) replicon. This compound induced a reduction of viral RNA and protein levels when acting in the low nanomolar range. Moreover, the compound could suppress replicon rebound in drug-treated cells and exhibited additive to synergistic effects when combined with protease inhibitor BILN 2061 or with IFN-α-2a. Our results demonstrate the potential use of tetracarboxyphenylporphyrins as potent anti-HCV agents.

AB - Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the search for highly selective protein-binding molecules capable of disrupting the viral life cycle, we have identified a class of anionic tetraphenylporphyrins as potent and specific inhibitors of the HCV replicons. Based on the structure-activity relationship studies reported herein, meso-tetrakis-(3,5- dicarboxy-4,4′-biphenyl) porphyrin was found to be the most potent inhibitor of HCV genotype 1b (Con1) replicon systems but was less effective against the genotype 2a (JFH-1) replicon. This compound induced a reduction of viral RNA and protein levels when acting in the low nanomolar range. Moreover, the compound could suppress replicon rebound in drug-treated cells and exhibited additive to synergistic effects when combined with protease inhibitor BILN 2061 or with IFN-α-2a. Our results demonstrate the potential use of tetracarboxyphenylporphyrins as potent anti-HCV agents.

UR - http://www.scopus.com/inward/record.url?scp=73849147890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849147890&partnerID=8YFLogxK

U2 - 10.1128/AAC.01206-09

DO - 10.1128/AAC.01206-09

M3 - Article

VL - 54

SP - 197

EP - 206

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -